Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.
- Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.
- Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.
- Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.
- https://stocktwits.com/news-articles/markets/equity/sls-stock-sparks-retail-buzz-ahead-of-aacr-presentation-on-experimental-cancer-therapy/cZJy282RIUY
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.